There is a strong relationship between prolonged, low-level radon exposure and lung cancer, indicating a need for enhanced protection measures, according to a study led by the University of California, Irvine.
After Novartis failed in an attempt to repurpose canakinumab for metastatic non-small cell lung cancer (NSCLC), the Swiss company said it supported continued exploration of the medication in earlier stages of the disease.
Takeda recently launched a value-based pricing program for its lung cancer drug Alunbrig.
An artificial intelligence (AI) program can spot signs of lung cancer on CT scans a year before they can be diagnosed with existing methods.
Read More
Adding Libtayo to chemotherapy significantly improved median overall survival in advanced non-small cell lung cancer patients from 13 to 22 months, leading to a 29% reduction in the risk of death, compared to chemotherapy alone.
Read More
A new study found that reduced-dose CT imaging was able to detect more than 90% of lung nodules in young adults.
Read More
Chronic viral infections and cancer can cause “killer” T cells in the immune system to take on a state of dysfunction or exhaustion whereby they can no longer react to infectious invaders or abnormal cells like normal “memory” T cells.
Read More
Reduced-dose CT depicts greater than 90% of lung nodules in children and young adults with cancer, identifying the presence of nodules with moderate sensitivity and high specificity.
Read More
A research team has been able to reliably identify tumor type using a combination of infrared microscopy and artificial intelligence.
Read More
An incidental lung nodule program found lung cancer with higher frequency than the majority of low-dose CT scans, new research shows.
Read More
An increase in glucose production from circadian disregulation may fuel lung cancer growth.
Read More
Combining immunotherapy with targeted radiation resulted in a greater response rate than immunotherapy alone in a phase 2 clinical trial in patients with early-stage, non-small-cell lung cancer.
Read More
A new study, reported in Oncotarget, found that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
Read More
The FDA approved sotorasib (Lumakras, Amgen Inc) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C.
Read More
The FDA has approved Janssen Pharma’s Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Read More